MLAB CFO John Sakys Buys Shares
On June 15, 2026, MLAB's CFO, John Sakys, purchased 8,416 shares.
Key Points
- John Sakys, CFO of MLAB, bought 8,416 shares on June 15, 2026, with the stock trading at $104.08.
- MLAB's stock is trading near $104.08, with recent institutional activity showing mixed changes in holdings.
- Analysts have set varied price targets for MLAB, with Wells Fargo maintaining a 'hold' rating as of February 4, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
John Sakys, the Chief Financial Officer of MLAB, made a significant purchase of company shares on June 15, 2026. He acquired 8,416 shares, with the stock trading at $104.08 at the time of the transaction. This move was not planned under a Rule 10b5-1 trading plan.
Insider Buying and Selling at Mesa Laboratories, Inc.
On the same day, John Sakys also sold 3,951 shares, while Brian David Archbold, Senior Vice President of Operations, bought 4,328 shares and sold 1,780 shares. These transactions reflect active insider trading activity within the company.
Other Institutional Activity in MLAB
Long Path Partners LP significantly increased its holdings by 178,360 shares, ending with 405,583 shares valued at about $35.9 million. BlackRock, Inc., however, slightly reduced its position by 4,815 shares, now holding 393,851 shares worth approximately $34.8 million. Boston Partners added 55,335 shares, bringing its total to 268,711 shares, valued at $23.8 million. Select Equity Group, L.P. increased its stake by 29,450 shares to 235,885 shares, valued at $20.9 million. Meanwhile, Vanguard Capital Management LLC initiated a position with 232,643 shares, valued at $20.6 million.
Mesa Laboratories, Inc. Stock Down 19.3%
Shares of MLAB are currently trading around $104.08. The stock has seen varied activity from institutional investors, reflecting differing views on its valuation and growth prospects.
$MLAB stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On February 4, 2026, Wells Fargo maintained its 'hold' rating for MLAB, with a price target of $94. Earlier, on December 15, 2025, the firm had set a target of $83. Evercore ISI has consistently maintained a 'buy' rating, with a target of $106 as of July 2, 2024.
Bottom Line
John Sakys' purchase of MLAB shares highlights insider confidence in the company's prospects. Institutional investors have shown mixed sentiments, with some increasing their stakes while others have trimmed their holdings. Analysts remain cautious, with a range of ratings and price targets. As always, these insights reflect past actions and may not indicate future performance.
Get Mesa Laboratories, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MLAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.